Fox Chase Researchers Selected to Present at ECOG-ACRIN Young Investigator Symposium

Vijayvergia’s presentation was entitled, “Transcript profiling of neuroendocrine tumors to identify new targets and mechanism of progression.”
Vijayvergia’s presentation was entitled, “Transcript profiling of neuroendocrine tumors to identify new targets and mechanism of progression.”

PHILADELPHIA (October 30, 2018)— Namrata (Neena) Vijayvergia, MD, assistant chief of Gastrointestinal Medical Oncology, and Alexander Deneka, MD, PhD, postdoctoral fellow, both at Fox Chase Cancer Center, were among seven scientists selected to present at the Young Investigator Symposium at the semiannual ECOG-ACRIN Cancer Research Group meeting on October 25 in Fort Lauderdale, Florida.

The Young Investigator Symposium is a professional mentoring event at which early-career scientists meet experienced investigators, learn about research opportunities, and share new research approaches. Presenters are selected by a committee after a competitive application process. They each deliver a 10-minute oral presentation on their research and respond to attendees’ questions.

A closeup photo of Alexander Deneka, MD, PhD, turning around to look at the camera with several monitors on a desk behind him.
Deneka’s presentation was entitled, “Synthetic lethal targeting of mitotic checkpoints in HPV-negative head and neck cancer.”

Vijayvergia’s presentation was entitled, “Transcript profiling of neuroendocrine tumors to identify new targets and mechanism of progression.” Deneka’s was entitled, “Synthetic lethal targeting of mitotic checkpoints in HPV-negative head and neck cancer.”

Up to eight individuals present at the Young Investigator Symposium each year. They are selected on the basis of scientific innovation, significance, and the potential for clinical impact. In addition to their presentations, the selected researchers observe scientific committee meetings, participate in educational sessions on clinical trials, and network with more experienced attendees.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427

Resize Text